ERBB2 and breast cancer: In a pooled analysis of 33 studies with 57,531 clinically node-positive patients before NAST axillary pCR according to subtypes were reported in 60% (hormone receptor-negative/HER2-positive), 59% (HER2-positive/hormone receptor-negative or positive), 48% TNBC, 45% (hormone receptor-positive/HER2-positive), 35% (luminal B), 18% (hormone receptor-positive/HER2-negative), and 13% (luminal A) breast cancer [16].